Navigation Links
Histogen’s Composition for Hair Growth Receives US Patent
Date:9/17/2013

San Diego, CA (PRWEB) September 17, 2013

Histogen, Inc., a regenerative medicine company developing innovative therapies based on the products of cells grown under simulated embryonic conditions, today announced that the United States Patent & Trademark Office has issued patent 8,535,913, entitled “Soluble Composition for Promoting Hair Growth Produced by Hypoxic Culture of Fibroblast Cells”.

The patent, which is the fourth US patent issued to the Company, covers the liquid composition of proteins and cofactors that is secreted by multipotent stem cells through Histogen’s technology process, and the method of administering that composition to stimulate hair growth. Histogen’s Hair Stimulating Complex (HSC), covered by this new patent, is in clinical development as an injectable treatment for male pattern and female diffuse hair loss.

“We are extremely pleased that HSC, and future hair restoration treatments using this technology, are now bolstered by a US patent,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “At a time when the industry continues to uncover information about how cell-signaling results in hair growth and maintenance, patent protection for our unique composition of proteins and growth factors is of great benefit to Histogen and its future partners.”

Several factors critical to hair growth such as follistatin, VEGF and KGF, are present in HSC, and their secretion by the cells is stimulated by low oxygen and special culture conditions utilized by Histogen. The conditions under which the cells are manufactured not only upregulates genes associated with hair growth, but induces significantly increased production of these critical factors than seen with traditional culture conditions.

In two Company-sponsored clinical trials, HSC has resulted in statistically significant increases across hair growth parameters, including hair count, density and thickness. In addition, the treatment has shown efficacy in difficult-to-treat patient groups, including women, older subjects and those with temporal recession region hair loss. Histogen looks forward to progressing HSC to the next clinical stage, and to further analyzing its newly-patented composition.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11129502.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen’s Method of Generating Multipotent Stem Cells Receives US Patent
2. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
3. Bio/Pharmaceutical Contract Manufacturing - Industry Analysis of Dose Manufacturing by the Numbers: Composition, Size, Market Shares, Profitability and Outlook
4. Downsizing and the Need for Increased Selling Effectiveness Fuel Delta Points Growth
5. RSB Spine, LLC Announces 2011 Revenue Growth
6. ERT Launches New Website to Support Significant Commercial Growth
7. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
8. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
9. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
10. Carbon nanotubes can double growth of cell cultures important in industry
11. CannaBANK Acquires Rights to License PharmaSpheres Patented Growth System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... Open Therapeutics and ... (IP) sharing and commercialization model. , The Center for Advancing Innovation helps institutions ... this effort is bringing the IP to the attention of the entrepreneurial community ...
(Date:4/19/2017)... (PRWEB) , ... April 18, 2017 , ... ... 1970s and has been a key device for generating monodisperse droplets of known ... droplet processes and for generating monodisperse solid particles by drying monodisperse droplets. ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics ... Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial ... an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in ...
(Date:4/19/2017)... 19, 2017 A new report published by Allied Market ... ," the global market was valued at $6,769 million in 2015, and is ... 2016 to 2022. ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) The cross-flow segment ...
Breaking Biology Technology:
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):